Sharing learning and knowledge about how ReQoL can be used to support person-centred, recovery-focused mental health services.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
The Clinical Outcomes team will be attending The International Congress of Parkinson’s Disease and Movement Disorders®
Dr David Churchman to represent the Clinical Outcomes team at the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France, from the 22nd - 26th September 2019.
ISPOR seeking input for discussions on developing “guiding principles” for COAs in real-world studies!
ISPOR Clinical Outcome Assessment Special Interest Group will be hosting a virtual roundtable meeting to examine ISPOR members’ opinions on developing guiding principles for the use of COAs in real world studies.
The Oxford Participation and Activities Questionnaire (OxPAQ) – Further validation for use in three more conditions
The generic Patient Reported Outcome (PRO) measure – the Oxford Participation and Activities Questionnaire (OxPAQ) has been further validated for use in three more common conditions.
The Oxford Participation and Activities Questionnaire (OxPAQ) – Minimal Important Differences (MID) and effect sizes are now available!
Minimal Important Difference (MID) and Effect Sizes for the measure’s domains now available
Producing QALY’s: Diabetes-specific preference-based measures for health economics and outcomes research
The Clinical Outcomes team at Oxford University Innovation are very pleased to announce the availability of diabetes-specific preference-based measures that can be used to produce valuable health economic data.
The Oxford Participation and Activities Questionnaire (OxPAQ) has now been validated for other conditions
The OxPAQ is now validated for use in Chronic obstructive pulmonary disease (COPD), Aneurysmal subarachnoid haemorrhage (AHS) and Valvular heart disease.